Physician profile
Brian Y Ng
NPI 1659345387
$5,252.53
in general payments reported to CMS, 2019-2025
12 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $579 · 2021: $836 · 2022: $1,017 · 2023: $767 · 2024: $988 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Education: $41.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.32 |
| Education | $41.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,469.25 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,291.31 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $311.60 | 2019-2025 | Linzess |
| Celgene Corporation | $282.85 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $248.00 | 2019-2025 | Exalt Model D, Dreamtome Rx 49, Alliance II |
| Takeda Pharmaceuticals U.S.A., INC. | $218.49 | 2022-2025 | Entyvio |
| Celltrion USA INC. | $110.12 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $108.33 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $94.20 | 2019 | |
| Genzyme Corporation | $93.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.45 | 2019 | |
| Braintree Laboratories, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.